European journal of nuclear medicine and molecular imaging · 2025
RECIP 1.0 more predictive of overall survival than PSMA PET progression criteria in biochemically recurrent prostate cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Molin Kaylee, Ong Jeremy S L, Werf Steven Van Der, Francis Roslyn J, Hassan Ghulam Mubashar, Ebert Martin A, Kendrick Jake
Аннотация
PURPOSE: Up to 40% of prostate cancer (PCa) patients experience biochemical recurrence (BCR) after primary treatment, but reliable tools for risk stratification in this setting are limited. This study compared Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) and PSMA PET Progression (PPP) criteria in predicting overall survival (OS) and prostate-specific antigen progression-free survival (PSA-PFS). As a secondary aim, PROMISE-based nomograms were assessed as tools for OS prediction.
METHODS: A cohort of 154 BCR PCa patients with baseline and follow-up [68Ga]Ga-PSMA-11 PET/CT was analysed. Disease progression was defined by RECIP 1.0 and three PPP variants (PPP-Volume, PPP-Mean SUV, PPP-Max SUV). Associations with OS and PSA-PFS were tested using Kaplan-Meier and Cox regression models. PROMISE-based visual and quantitative nomograms were applied to follow-up scans to predict OS. Subgroup analyses by treatment type were performed for RECIP and PPP criteria.
RESULTS: RECIP-defined progressive disease (RECIP-PD) was most strongly associated with OS, identifying patients at highest risk of death (median OS 53.2 months; HR 4.62; 95% CI: 2.41-8.87; p < 0.001). PPP-based criteria were also prognostic for OS, and were the only framework associated with PSA-PFS. PROMISE-based nomograms were predictive of OS, with performance comparable to PPP criteria. By treatment type, RECIP-PD performed best in androgen deprivation therapy, PPP-Max SUV in radiotherapy, and PPP-Volume in combined ADT + radiotherapy. SUV-based PPP criteria were most predictive of PSA-PFS in combined ADT + radiotherapy.
CONCLUSION: In BCR PCa, RECIP 1.0 best predicts OS, PPP criteria better predict PSA progression, and PROMISE nomograms provide a single-timepoint approach to OS risk stratification.
TRIAL REGISTRATION NUMBER: ACTRN ACTRN12615000608561. Registered 11 June 2015. Retrospectively registered.
METHODS: A cohort of 154 BCR PCa patients with baseline and follow-up [68Ga]Ga-PSMA-11 PET/CT was analysed. Disease progression was defined by RECIP 1.0 and three PPP variants (PPP-Volume, PPP-Mean SUV, PPP-Max SUV). Associations with OS and PSA-PFS were tested using Kaplan-Meier and Cox regression models. PROMISE-based visual and quantitative nomograms were applied to follow-up scans to predict OS. Subgroup analyses by treatment type were performed for RECIP and PPP criteria.
RESULTS: RECIP-defined progressive disease (RECIP-PD) was most strongly associated with OS, identifying patients at highest risk of death (median OS 53.2 months; HR 4.62; 95% CI: 2.41-8.87; p < 0.001). PPP-based criteria were also prognostic for OS, and were the only framework associated with PSA-PFS. PROMISE-based nomograms were predictive of OS, with performance comparable to PPP criteria. By treatment type, RECIP-PD performed best in androgen deprivation therapy, PPP-Max SUV in radiotherapy, and PPP-Volume in combined ADT + radiotherapy. SUV-based PPP criteria were most predictive of PSA-PFS in combined ADT + radiotherapy.
CONCLUSION: In BCR PCa, RECIP 1.0 best predicts OS, PPP criteria better predict PSA progression, and PROMISE nomograms provide a single-timepoint approach to OS risk stratification.
TRIAL REGISTRATION NUMBER: ACTRN ACTRN12615000608561. Registered 11 June 2015. Retrospectively registered.